Corporate News – Evotec SE
Evotec SE (ticker: EVT.DE) closed the trading session on Wednesday, 21 March 2026, at a level 3.5 % higher than the previous close. At 20:54 Central Europe time the share price was quoted at approximately EUR 2.86 on major exchanges. The company has an outstanding share count of 177.7 million and a market capitalization of EUR 465 million. In the last 24 hours, roughly EUR 3 million worth of shares changed hands, corresponding to a volume of around 1.05 million shares. Compared with the end of the previous month, the share price has declined by 2.58 %. The 200‑day simple moving average stands at EUR 4.51. Over the past 52 weeks, the highest price reached EUR 7.30 on 27 October 2025, while the lowest price was EUR 2.41 on 13 October 2026.
Regulatory Filings and Market Position
The German Federal Gazette reported that various market participants hold net short positions in Evotec SE. These disclosed positions, recorded between mid‑August and mid‑September, represent a small fraction of the company’s issued share capital. In the same period, Evotec’s shares were among the best‑performing constituents of both the TecDAX and SDAX indices, recording modest gains at the close of the day. The short‑selling disclosures are routine regulatory filings and do not indicate any extraordinary corporate action. Overall, the company’s market standing remains stable, with its share price showing a modest upward drift during the reporting week.
Related Stock Performance (Last 24 Hours)
| Company | Ticker | % Change | Current Price (EUR) | Market Cap (EUR mn) | P/E Ratio |
|---|---|---|---|---|---|
| Innoscripta | 1INN.DE | –2.58 % | 45.65 | 435 | 17.03 |
| Patrizia | PAT.DE | +1.90 % | 6.45 | 544.6 | 18.88 |
| Mensch Und Maschine Software | MUM.DE | –5.33 % | 34.1 | 552.4 | 17.30 |
| Grenke | GLJ.DE | –1.18 % | 10.06 | 438.2 | 7.35 |
| Init Innovation Traffic | IXX.DE | –0.94 % | 42.9 | 460.9 | 19.35 |
Highlights
Patrizia SE announced the expansion of its European food‑retail platform through the acquisition of 24 newly built Lidl supermarkets across France, Italy, and Spain. The portfolio covers roughly 50,000 m² and is fully leased to Lidl’s local operating companies on long‑duration, CPI‑linked contracts, reinforcing the group’s focus on resilient, inflation‑protected real‑estate assets. The acquisition builds on more than two decades of experience in the sector and strengthens Patrizia’s long‑standing partnership with Lidl, while enlarging its investment presence in Southern Europe. The company highlighted alignment with broader structural trends such as urbanisation and sustained demand for well‑located essential retail, underscoring its strategy of selective capital deployment in defensively positioned assets.
Mensch Und Maschine Software SE reported its third‑quarter results for 2026, showing continued growth in its core CAD/CAM/BIM segment while the digitisation arm faced headwinds linked to the Autodesk partnership. The company highlighted a sustained rise in sales, with the software segment delivering a notable increase in gross profit, whereas the digitisation segment’s profit was dampened by external factors. Operating costs remained below the previous year, supporting a modest improvement in EBITDA. Management expressed confidence that the anticipated drag from the Autodesk relationship would lessen in the final quarter and that the firm’s cost‑streamlining efforts would enable it to reach its medium‑term earnings targets. The company reiterated its long‑term objective of doubling earnings per share by 2030, citing ongoing AI initiatives and natural‑language database queries as key differentiators.
Company Overview
Evotec SE is a pharmaceutical company specializing in drug discovery solutions across multiple therapeutic areas, including neuroscience, diabetes, pain and inflammation, oncology, infectious diseases, respiratory, and fibrosis. The company serves pharmaceutical and biotechnology clients worldwide, aiming to develop innovative therapies that address unmet medical needs.
